Compare Sanofi SA (SNY) vs Uber Technologies Inc (UBER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Uber Technologies Inc — how do they compare? Sanofi SA trades at $42.71 (market cap $104.06B), while Uber Technologies Inc trades at $71.65 (market cap $149.37B). The key difference: Uber Technologies Inc is the larger of the two by market cap, and Sanofi SA pays a 5.61% dividend while Uber Technologies Inc pays none. Which is the better fit depends on your goals.
| SNY | UBER | |
|---|---|---|
Market Cap | $104.06B | $149.37B |
Sector | Health | Industrials |
52-Week High | $52.34 | $100.10 |
52-Week Low | $41.33 | $65.94 |
Enterprise Value | $124.09B | $158.71B |
Dividend Yield | 5.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sanofi (SNY) trades at $43.155, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported strong Q2 2026 earnings, beating expectations with EPS of $1.21 versus $1.10 expected, and raised full-year guidance. Recent FDA approvals for COVID vaccines and EU approval for MenQuadfi in infants provide positive catalysts, though pipeline setbacks with an eczema drug withdrawal create uncertainty.
SNY presents a mixed outlook with solid fundamentals including a 5.4% dividend yield and reasonable valuation (P/E 22.94), but faces execution risks under new CEO leadership. Analyst consensus leans Hold (51.86%) with price target of $49.50, suggesting moderate upside potential. Key risks include drug pipeline challenges and competitive pressures in the pharmaceutical sector.
Uber's stock trades at $71.08, down 6.18% today, amid a bearish technical signal but strong fundamentals. Revenue grew to $52.02B in 2025 with a net income of $10.05B, though Q4 2025 earnings missed expectations. Recent news highlights strategic shifts toward autonomous vehicles, including robotaxi pilots in Spain and Germany, alongside cost-cutting measures like HR layoffs and AI spending caps.
The outlook is mixed: robust revenue growth and a dominant market position support upside, but competitive pressures, regulatory risks, and a projected negative cash flow in 2026 pose challenges. Analyst consensus is strongly bullish with a $102.56 price target, suggesting significant potential if execution aligns with autonomous vehicle initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Uber Technologies Inc
Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food delivery service providers, and shippers with carriers. The firm's on-demand technology platform could eventually be used for additional products and services, such as autonomous vehicles, delivery via drones, and Uber Elevate, which, as the firm refers to it, provides aerial ride-sharing. Uber Technologies is headquartered in San Francisco and operates in over 63 countries with over 110 million users that order rides or foods at least once a month. Approximately 76% of its gross revenue comes from ride-sharing and 22% from food delivery.
Read more on UBER →
